EP4053157A4 - PROTEIN FUSED WITH A DISEASE ANTIGEN AND CORRESPONDING USE - Google Patents

PROTEIN FUSED WITH A DISEASE ANTIGEN AND CORRESPONDING USE Download PDF

Info

Publication number
EP4053157A4
EP4053157A4 EP20883248.5A EP20883248A EP4053157A4 EP 4053157 A4 EP4053157 A4 EP 4053157A4 EP 20883248 A EP20883248 A EP 20883248A EP 4053157 A4 EP4053157 A4 EP 4053157A4
Authority
EP
European Patent Office
Prior art keywords
fused protein
disease antigen
antigen
disease
fused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20883248.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4053157A1 (en
Inventor
Jee Won Lee
Bo Ram Lee
Chul Joo YOON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellemedy Co Ltd
Original Assignee
Cellemedy Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellemedy Co Ltd filed Critical Cellemedy Co Ltd
Priority claimed from PCT/KR2020/015164 external-priority patent/WO2021086158A1/ko
Publication of EP4053157A1 publication Critical patent/EP4053157A1/en
Publication of EP4053157A4 publication Critical patent/EP4053157A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20883248.5A 2019-11-01 2020-11-02 PROTEIN FUSED WITH A DISEASE ANTIGEN AND CORRESPONDING USE Pending EP4053157A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190138580 2019-11-01
PCT/KR2020/015164 WO2021086158A1 (ko) 2019-11-01 2020-11-02 질환 항원이 융합된 단백질 및 이의 용도

Publications (2)

Publication Number Publication Date
EP4053157A1 EP4053157A1 (en) 2022-09-07
EP4053157A4 true EP4053157A4 (en) 2023-12-27

Family

ID=75915217

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20883248.5A Pending EP4053157A4 (en) 2019-11-01 2020-11-02 PROTEIN FUSED WITH A DISEASE ANTIGEN AND CORRESPONDING USE
EP20880696.8A Pending EP4053153A4 (en) 2019-11-01 2020-11-02 PROTEIN FUSED WITH A MOLECULE CAPABLE OF BINDING AN IMMUNE CHECKPOINT MOLECULE AND USE THEREOF

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20880696.8A Pending EP4053153A4 (en) 2019-11-01 2020-11-02 PROTEIN FUSED WITH A MOLECULE CAPABLE OF BINDING AN IMMUNE CHECKPOINT MOLECULE AND USE THEREOF

Country Status (2)

Country Link
EP (2) EP4053157A4 (ko)
KR (2) KR102562878B1 (ko)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053434A1 (en) * 2016-09-16 2018-03-22 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
EP3501509A1 (en) * 2016-07-15 2019-06-26 Korea Institute of Science and Technology Novel nanocage and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101604375B1 (ko) * 2013-02-08 2016-03-25 경북대학교 산학협력단 인간 페리틴 유래 융합폴리펩티드
KR101630858B1 (ko) * 2014-01-24 2016-06-15 울산과학기술원 항원 펩타이드-페리틴 융합단백질 및 이를 포함하는 백신 조성물
KR102389169B1 (ko) * 2015-10-22 2022-04-21 고려대학교 산학협력단 암 특이적 에피토프와 연결된 단백질 나노입자 및 이를 포함하는 암 면역치료용 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3501509A1 (en) * 2016-07-15 2019-06-26 Korea Institute of Science and Technology Novel nanocage and use thereof
WO2018053434A1 (en) * 2016-09-16 2018-03-22 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EUN JUNG LEE ET AL: "Nanocage-Therapeutics Prevailing Phagocytosis and Immunogenic Cell Death Awakens Immunity against Cancer", ADVANCED MATERIALS, VCH PUBLISHERS, DE, vol. 30, no. 10, 15 January 2018 (2018-01-15), pages n/a, XP071871297, ISSN: 0935-9648, DOI: 10.1002/ADMA.201705581 *
LEE BO-RAM ET AL: "Human Ferritin Platform and Its Optimized Structures to Enhance Anti-Cancer Immunity", vol. 4, no. 2, 21 December 2020 (2020-12-21), XP093097860, ISSN: 2366-3987, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/adtp.202000208> DOI: 10.1002/adtp.202000208 *
NEEK MEDEA ET AL: "Protein-based nanoparticles in cancer vaccine development", NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE, ELSEVIER, AMSTERDAM, NL, vol. 15, no. 1, 4 October 2018 (2018-10-04), pages 164 - 174, XP085558014, ISSN: 1549-9634, DOI: 10.1016/J.NANO.2018.09.004 *
See also references of WO2021086158A1 *

Also Published As

Publication number Publication date
KR102562878B1 (ko) 2023-08-03
KR20210053251A (ko) 2021-05-11
EP4053153A4 (en) 2023-12-20
KR20210053252A (ko) 2021-05-11
EP4053157A1 (en) 2022-09-07
EP4053153A1 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
EP3805264A4 (en) ANTI-INTERLEUKIN 17A ANTIBODIES, PHARMACEUTICAL COMPOSITION AND USE
EP3817769A4 (en) HUMAN ANTI-CD47 ANTIBODIES AND THEIR USES
EP3887403A4 (en) ANTI-4-1BB ANTIBODIES AND ITS USE
EP4039706A4 (en) ANTIBODIES TARGETING CLDN18.2, METHOD FOR PREPARATION AND USE
EP3992209A4 (en) CLDN18.2 ANTIBODY AND ITS USE
EP3680331A4 (en) MODIFIED CAS9 PROTEIN AND USING IT
EP3907240A4 (en) ANTI-TNFR2 ANTIBODIES AND ITS USE
EP3878956A4 (en) MODIFIED CAS9 PROTEIN AND RELATED USE
AU2018290633A1 (en) Conjugate of VEGF-Grab protein and drug, and use thereof
EP3964531A4 (en) PROTEIN MOLECULE AND USE THEREOF
EP3960756A4 (en) FLAGELLIN FUSION PROTEIN AND ITS USE
EP3858866A4 (en) GLP1-FC-FUSION PROTEIN AND CONJUGATE THEREOF
EP3962956A4 (en) ANTI-HVEM ANTIBODIES AND USE THEREOF
EP4082534A4 (en) PHARMACEUTICAL COMPOSITION AND PRODUCTION PROCESS THEREOF AND USE THEREOF
EP4032904A4 (en) ANTI-ALPHA HEMOLYSIN ANTIBODIES AND USE THEREOF
EP3882277A4 (en) FUSION PROTEIN AND ITS USE
EP3604343A4 (en) FUSION PROTEIN, MANUFACTURING METHOD THEREFOR AND USE THEREOF
EP4083212A4 (en) MUTANT RSV-F PROTEIN AND ITS USE
EP3805386A4 (en) MODIFIED CAS9 PROTEIN AND USE THEREOF
EP4083055A4 (en) SUGAR-MODIFIED PROTEIN
EP4050130A4 (en) ALUMINUM OXIDE GRAIN, PROCESS FOR ITS PRODUCTION AND ITS USE
EP4043012A4 (en) MEDICINAL PRODUCTS FOR TREATING ARTERY DISEASES AND USE THEREOF
EP3856242A4 (en) ANTI-SIGLEC ANTIBODIES, PHARMACEUTICAL COMPOSITION COMPRISING IT, AND THEIR USES
EP3966321A4 (en) ASX-SPECIFIC PROTEIN LIGASES AND USES THEREOF
EP3864157A4 (en) INSECTICIDAL PROTEINS AND METHODS OF USE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220525

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231123

RIC1 Information provided on ipc code assigned before grant

Ipc: B82Y 5/00 20110101ALI20231117BHEP

Ipc: A61P 35/00 20060101ALI20231117BHEP

Ipc: A61K 9/00 20060101ALI20231117BHEP

Ipc: A61K 9/19 20060101ALI20231117BHEP

Ipc: A61K 9/51 20060101ALI20231117BHEP

Ipc: A61K 39/385 20060101ALI20231117BHEP

Ipc: A61K 39/00 20060101ALI20231117BHEP

Ipc: C07K 16/28 20060101ALI20231117BHEP

Ipc: C07K 14/47 20060101AFI20231117BHEP